Related Experiment Videos

[Experimental aspergillosis in mice]

Dermatologica
|January 1, 1979
PubMed

Insights

This study evaluates a mouse model for screening antifungal drugs against Aspergillus fumigatus. Intravenous infection effectively induced lethal aspergillosis, showing promise for antimycotic drug development.

Area of Science:

  • Medical Mycology
  • Pharmacology

Background:

  • Aspergillosis, a fungal infection caused by Aspergillus species, poses a significant threat, necessitating effective treatments.
  • Developing new antimycotic agents requires reliable preclinical models to assess therapeutic efficacy.

Purpose of the Study:

  • To evaluate the utility of experimentally induced murine aspergillosis as a model for screening novel antimycotic compounds.
  • To investigate the differences between the mouse model and human aspergillus infections.

Main Methods:

  • Mice were infected intravenously with Aspergillus fumigatus spores ( > 10^6) to induce kidney abscesses and lethal infection.
  • Intratracheal inoculation with 2 x 10^6 spores did not result in observable symptoms.
  • The efficacy of various antimycotic agents, including amphotericin B, 5-fluorocytosine, and the imidazole derivative BAY h 4364, was assessed.

Main Results:

  • Intravenous infection with a high dose of Aspergillus fumigatus spores reliably induced acute, lethal aspergillosis in mice, characterized by kidney abscess formation.
  • Intratracheal administration of spores did not elicit a disease response.
  • Amphotericin B, 5-fluorocytosine, and BAY h 4364 demonstrated significant therapeutic efficacy in the mouse model.

Conclusions:

  • Experimentally induced murine aspergillosis via intravenous inoculation is a viable model for screening antimycotic drugs.
  • The model highlights key differences from human infections, particularly regarding infectious dose and route.
  • Effective agents like amphotericin B, 5-fluorocytosine, and BAY h 4364 show promise for treating aspergillosis.

Related Concept Videos